BMS's Abecma Faces J&J Threat Despite Pivotal Success In Earlier Myeloma Setting
Both Rivals Tout Blockbuster Potential
The US major’s CAR-T therapy is likely to win a label expansion to the large third-line-plus myeloma setting following positive Phase III data but a rival candidate from J&J could nab more of the market.
